In the heightened microglial activation response, an exaggerated mROS/c-Abl/NLRP3 signaling axis was confirmed [109], which suggested that targeting the c-Abl-regulated NLRP3 inflammasome signaling offers a therapeutic strategy for PD. The gene discussed is NLRP3; the disease is Parkinson disease.